Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 725

1.

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.

Sader HS, Mendes RE, Pfaller MA, Flamm RK.

J Antimicrob Chemother. 2019 Feb 7. doi: 10.1093/jac/dkz006. [Epub ahead of print]

PMID:
30753485
2.

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the United States and Europe during 2012-2016 as part of a global surveillance programme.

Shortridge D, Duncan LR, Pfaller MA, Flamm RK.

Int J Antimicrob Agents. 2019 Feb 1. pii: S0924-8579(19)30022-6. doi: 10.1016/j.ijantimicag.2019.01.015. [Epub ahead of print]

PMID:
30716448
3.

In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States.

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK, Mendes RE.

Microb Drug Resist. 2019 Jan 29. doi: 10.1089/mdr.2018.0410. [Epub ahead of print]

PMID:
30694735
4.

Frequency and Antimicrobial Susceptibility of Bacterial Isolates from Patients Hospitalised with Community-Acquired Skin and Skin Structure Infection in Europe, Asia, and Latin America.

Sader HS, Streit JM, Carvalhaes CG, Huband MD, Pfaller MA.

J Glob Antimicrob Resist. 2018 Nov 17. pii: S2213-7165(18)30229-7. doi: 10.1016/j.jgar.2018.11.013. [Epub ahead of print]

PMID:
30458298
5.

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.

Pfaller MA, Flamm RK, Mendes RE, Streit JM, Smart JI, Hamed KA, Duncan LR, Sader HS.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01566-18. doi: 10.1128/AAC.01566-18. Print 2019 Jan.

PMID:
30373807
6.

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.

Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL, Castanheira M.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01230-18. doi: 10.1128/AAC.01230-18. Print 2018 Oct.

7.

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Van Dijck P, Sjollema J, Cammue BP, Lagrou K, Berman J, d'Enfert C, Andes DR, Arendrup MC, Brakhage AA, Calderone R, Cantón E, Coenye T, Cos P, Cowen LE, Edgerton M, Espinel-Ingroff A, Filler SG, Ghannoum M, Gow NAR, Haas H, Jabra-Rizk MA, Johnson EM, Lockhart SR, Lopez-Ribot JL, Maertens J, Munro CA, Nett JE, Nobile CJ, Pfaller MA, Ramage G, Sanglard D, Sanguinetti M, Spriet I, Verweij PE, Warris A, Wauters J, Yeaman MR, Zaat SAJ, Thevissen K.

Microb Cell. 2018 Jun 14;5(7):300-326. doi: 10.15698/mic2018.07.638. Review.

8.

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

J Antimicrob Chemother. 2018 Oct 1;73(10):2748-2756. doi: 10.1093/jac/dky235.

PMID:
29982565
10.

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.

Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D, Jones RN.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00339-18. doi: 10.1128/JCM.00339-18. Print 2018 Aug.

11.

Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.

Pfaller MA, Rhomberg PR, Castanheira M.

Diagn Microbiol Infect Dis. 2018 Sep;92(1):43-45. doi: 10.1016/j.diagmicrobio.2018.04.005. Epub 2018 Apr 13.

PMID:
29735424
12.

Impact of rapid, culture-independent diagnosis of candidaemia and invasive candidiasis in a community health system.

Patch ME, Weisz E, Cubillos A, Estrada SJ, Pfaller MA.

J Antimicrob Chemother. 2018 Mar 1;73(suppl_4):iv27-iv30. doi: 10.1093/jac/dky046.

PMID:
29608750
13.

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):179-183. doi: 10.1016/j.diagmicrobio.2018.01.019. Epub 2018 Feb 24.

PMID:
29571839
14.

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):199-204. doi: 10.1016/j.diagmicrobio.2018.01.029. Epub 2018 Feb 3.

PMID:
29567128
15.

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.

Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M.

Int J Antimicrob Agents. 2018 Aug;52(2):144-150. doi: 10.1016/j.ijantimicag.2018.02.021. Epub 2018 Mar 3.

PMID:
29510189
16.

Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values.

Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Dannaoui E, Garcia-Effron G, Guinea J, Kidd S, Pelaez T, Sanguinetti M, Meletiadis J, Botterel F, Bustamante B, Chen YC, Chakrabarti A, Chowdhary A, Chryssanthou E, Córdoba S, Gonzalez GM, Guarro J, Johnson EM, Kus JV, Lass-Flörl C, Linares-Sicilia MJ, Martín-Mazuelos E, Negri CE, Pfaller MA, Tortorano AM.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01916-17. doi: 10.1128/AAC.01916-17. Print 2018 Apr.

17.

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).

Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS.

Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.

PMID:
29410368
18.

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).

Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS.

Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.

19.

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

Pfaller MA, Huband MD, Shortridge D, Flamm RK.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02327-17. doi: 10.1128/AAC.02327-17. Print 2018 Apr.

20.

Erratum for Pfaller et al., "In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014".

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02383-17. doi: 10.1128/AAC.02383-17. Print 2018 Feb. No abstract available.

21.

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).

Pfaller MA, Sader HS, Castanheira M, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2018 Apr 1;73(4):916-922. doi: 10.1093/jac/dkx485.

PMID:
29294031
22.

Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).

Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE.

Int J Antimicrob Agents. 2018 Apr;51(4):608-611. doi: 10.1016/j.ijantimicag.2017.12.011. Epub 2017 Dec 23.

PMID:
29277526
23.

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.

Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02397-17. doi: 10.1128/AAC.02397-17. Print 2018 Mar.

24.

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01555-17. doi: 10.1128/AAC.01555-17. Print 2018 Feb.

25.

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):143-147. doi: 10.1016/j.diagmicrobio.2017.10.010. Epub 2017 Oct 19.

PMID:
29157954
26.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.

Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01856-17. doi: 10.1128/AAC.01856-17. Print 2018 Jan.

28.
29.

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries.

Pfaller MA, Mendes RE, Streit JM, Hogan PA, Flamm RK.

J Antimicrob Chemother. 2017 Nov 1;72(11):3093-3099. doi: 10.1093/jac/dkx251.

PMID:
28961701
30.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK.

Braz J Infect Dis. 2017 Nov - Dec;21(6):627-637. doi: 10.1016/j.bjid.2017.06.008. Epub 2017 Sep 21.

31.

Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

Castanheira M, Deshpande LM, Davis AP, Rhomberg PR, Pfaller MA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00906-17. doi: 10.1128/AAC.00906-17. Print 2017 Oct.

32.

Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).

Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.

J Glob Antimicrob Resist. 2017 Dec;11:4-7. doi: 10.1016/j.jgar.2017.06.003. Epub 2017 Jul 19.

PMID:
28735053
33.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M.

J Glob Antimicrob Resist. 2017 Sep;10:186-194. doi: 10.1016/j.jgar.2017.05.025. Epub 2017 Jul 19.

PMID:
28735046
34.

In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Smart JI, Mendes RE.

Microb Drug Resist. 2017 Sep;23(6):718-726. doi: 10.1089/mdr.2017.0022. Epub 2017 Jul 20.

35.

CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.

Pfaller MA, Messer SA, Rhomberg PR, Castanheira M.

Int J Antimicrob Agents. 2017 Sep;50(3):352-358. doi: 10.1016/j.ijantimicag.2017.03.028. Epub 2017 Jul 6.

36.

Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Pfaller MA, Messer SA, Rhomberg PR, Borroto-Esoda K, Castanheira M.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00161-17. doi: 10.1128/AAC.00161-17. Print 2017 Aug.

37.

Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.

Shortridge D, Castanheira M, Pfaller MA, Flamm RK.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00465-17. doi: 10.1128/AAC.00465-17. Print 2017 Jul.

38.

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015).

Pfaller MA, Mendes RE, Streit JM, Hogan PA, Flamm RK.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00609-17. doi: 10.1128/AAC.00609-17. Print 2017 Jul.

39.

Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.

Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN, Sader HS.

Pediatr Infect Dis J. 2017 May;36(5):486-491. doi: 10.1097/INF.0000000000001477.

PMID:
28403050
40.

Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014).

Pfaller MA, Flamm RK, Duncan LR, Mendes RE, Jones RN, Sader HS.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):177-183. doi: 10.1016/j.diagmicrobio.2017.02.020. Epub 2017 Mar 6.

PMID:
28341098
41.

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.

Pfaller MA, Huband MD, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e00018-17. doi: 10.1128/AAC.00018-17. Print 2017 May.

42.

In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014.

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02609-16. doi: 10.1128/AAC.02609-16. Print 2017 Apr. Erratum in: Antimicrob Agents Chemother. 2018 Jan 25;62(2):.

43.
44.

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.

Pfaller MA, Messer SA, Rhomberg PR, Castanheira M.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02045-16. doi: 10.1128/AAC.02045-16. Print 2017 Mar.

45.

Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02411-16. doi: 10.1128/AAC.02411-16. Print 2017 Mar.

46.

Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate.

Pfaller MA, Mendes RE, Flamm RK, Jones RN, Sader HS.

Microb Drug Resist. 2017 Jul;23(5):571-579. doi: 10.1089/mdr.2016.0258. Epub 2016 Dec 5.

PMID:
27918694
47.
48.

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.

Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M.

J Antimicrob Chemother. 2016 Oct;71(10):2868-73. doi: 10.1093/jac/dkw214. Epub 2016 Jun 10.

49.

Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).

Castanheira M, Messer SA, Rhomberg PR, Pfaller MA.

Diagn Microbiol Infect Dis. 2016 Jun;85(2):200-4. doi: 10.1016/j.diagmicrobio.2016.02.009. Epub 2016 Feb 9.

PMID:
27061369
50.

International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method.

Espinel-Ingroff A, Colombo AL, Cordoba S, Dufresne PJ, Fuller J, Ghannoum M, Gonzalez GM, Guarro J, Kidd SE, Meis JF, Melhem TM, Pelaez T, Pfaller MA, Szeszs MW, Takahaschi JP, Tortorano AM, Wiederhold NP, Turnidge J.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1079-84. doi: 10.1128/AAC.02456-15. Print 2016 Feb.

Supplemental Content

Loading ...
Support Center